Login / Signup

Comparative efficacy and safety of anlotinib and topotecan as second-line treatment in small cell lung cancer: a retrospective cohort study.

Yang DuXiao-Yan LiuXiao-Yan SiXiao-Tong ZhangJing-Ya ZhouYi WangMin-Jiang ChenLi Zhang
Published in: Translational lung cancer research (2024)
Anlotinib shows the potential to extend PFS and manageable adverse events (AEs) compared to topotecan in the second-line setting for relapsed SCLC.
Keyphrases
  • small cell lung cancer
  • acute lymphoblastic leukemia
  • acute myeloid leukemia
  • diffuse large b cell lymphoma
  • multiple myeloma
  • hodgkin lymphoma
  • combination therapy
  • replacement therapy